1 Division of Cardiology Cardiovascular Center Seoul National University Bundang Hospital Seongnam Republic of Korea.
2 Department of Family Medicine Inje University Seoul Paik Hospital Seoul Republic of Korea.
J Am Heart Assoc. 2019 Feb 19;8(4):e011121. doi: 10.1161/JAHA.118.011121.
Background Many hospitalized patients with heart failure and reduced ejection fraction ( HF r EF ) have a slow heart rate at discharge, and the effect of β-blockers may be reduced in those patients. We sought to examine the variable effect of β-blockers on clinical outcomes according to the discharge heart rate of hospitalized HF r EF patients. Methods and Results The KorAHF (Korean Acute Heart Failure) registry consecutively enrolled 5625 patients hospitalized for acute heart failure. In this analysis, we included patients with HF r EF (left ventricular ejection fraction ≤40%). Slow heart rate was defined as <70 beats per minute regardless of the use of β-blockers. The primary outcome was 1-year all-cause postdischarge death according to heart rate. Among 2932 patients with HF r EF , 840 (29%) had a slow heart rate and 56% received β-blockers at discharge. Patients with slow heart rates were older and had lower 1-year mortality than those with high heart rates ( P<0.001). A significant interaction between discharge heart rate and β-blocker use was observed ( P<0.001 for interaction). When stratified, only patients without a β-blocker prescription and with a high heart rate showed higher 1-year mortality. In a Cox-proportional hazards regression analysis, β-blocker prescription at discharge was associated with 24% reduced risk for 1-year mortality in patients with high heart rates (hazard ratio: 0.76; 95% CI, 0.61-0.95) but not in those with slow heart rates (hazard ratio: 1.02; 95% CI, 0.68-1.55). Conclusions Many patients with acute heart failure have slow discharge heart rates, and β-blockers may have a limited effect on HF r EF and slow discharge heart rate. Clinical Trial Registration URL : http://www.clinicaltrial.gov . Unique identifier: NCT 01389843.
许多患有射血分数降低的心力衰竭(HF rEF)并出院的住院患者心率较慢,β受体阻滞剂在这些患者中的作用可能会降低。我们试图根据住院 HF rEF 患者的出院心率来检查β受体阻滞剂对临床结果的可变影响。
KorAHF(韩国急性心力衰竭)登记研究连续纳入 5625 例因急性心力衰竭住院的患者。在这项分析中,我们纳入了射血分数降低的心力衰竭(左心室射血分数≤40%)患者。无论是否使用β受体阻滞剂,心率较慢定义为<70 次/分钟。主要终点是根据心率确定的 1 年全因出院后死亡。在 2932 例 HF rEF 患者中,840 例(29%)心率较慢,56%在出院时使用β受体阻滞剂。心率较慢的患者年龄较大,1 年死亡率低于心率较快的患者(P<0.001)。出院时的心率与β受体阻滞剂使用之间存在显著的交互作用(交互作用 P<0.001)。分层后,只有未开具β受体阻滞剂处方且心率较高的患者 1 年死亡率较高。在 Cox 比例风险回归分析中,出院时开具β受体阻滞剂处方与心率较高的患者 1 年死亡率降低 24%相关(危险比:0.76;95%CI,0.61-0.95),但与心率较慢的患者无关(危险比:1.02;95%CI,0.68-1.55)。
许多急性心力衰竭患者的出院心率较慢,β受体阻滞剂可能对 HF rEF 和较慢的出院心率的作用有限。
http://www.clinicaltrial.gov。唯一标识符:NCT 01389843。